Flores G, Liang J J, Sierra A, Martínez-Fong D, Quirion R, Aceves J, Srivastava L K
Instituto de Fisiología, Universidad Autónoma de Puebla, México.
Neuroscience. 1999;91(2):549-56. doi: 10.1016/s0306-4522(98)00633-2.
We analysed the expression of dopamine receptor subtypes in the subthalamic nucleus by means of reverse transcriptase-polymerase chain reaction. We also studied, using autoradiography, all pharmacologically characterized dopamine receptors in four subregions of the subthalamic nucleus. For comparison, dopamine receptor subtypes were also evaluated in brain regions where they are more abundant and well characterized. The radioligands used were: [3H]SCH-23390, [3H]emonapride and [3H]2-dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene for dopamine D1, D2 and D3 receptors, respectively; and [3H]YM-09151-2 in the presence of raclopride for dopamine D4 receptors. Finally, we also evaluated the effect of unilateral 6-hydroxydopamine injection into the medial forebrain bundle on dopamine receptor levels expressed in the ipsilateral subthalamic nucleus. The lesion was estimated by decrease in the binding of [3H]WIN-35428, a specific dopamine transporter label. D1, D2 and D3 receptor messenger RNAs and binding sites were present in the subthalamic nucleus, but no messenger RNA for D4 receptors was found, although specific binding sites for these receptors were observed. As compared to the intact side, the 6-hydroxydopamine lesion did not change D1 receptors, increased D2 receptors, and decreased D3 receptors and the dopamine transporter. The results suggest that postsynaptic D1, D2 or D3 receptors can mediate the effect of dopamine on subthalamic nucleus neuronal activity. D4 receptors would mediate exclusively presynaptic effects. These results reinforce the idea that dopamine receptors in the subthalamic nucleus may play an important role in the physiology of the basal ganglia and in the pathophysiology of Parkinson's disease.
我们通过逆转录聚合酶链反应分析了丘脑底核中多巴胺受体亚型的表达。我们还使用放射自显影技术研究了丘脑底核四个亚区域中所有药理学特性明确的多巴胺受体。为了进行比较,还在多巴胺受体更丰富且特性明确的脑区评估了多巴胺受体亚型。所使用的放射性配体分别为:用于多巴胺D1、D2和D3受体的[3H]SCH - 23390、[3H]依莫必利和[3H]2 - 二丙基氨基 - 7 - 羟基 - 1,2,3,4 - 四氢萘;以及在雷氯必利存在下用于多巴胺D4受体的[3H]YM - 09151 - 2。最后,我们还评估了向内侧前脑束单侧注射6 - 羟基多巴胺对同侧丘脑底核中表达的多巴胺受体水平的影响。通过[3H]WIN - 35428(一种特异性多巴胺转运体标记物)结合的减少来评估损伤情况。丘脑底核中存在D1、D2和D3受体信使核糖核酸及结合位点,但未发现D4受体的信使核糖核酸,尽管观察到了这些受体的特异性结合位点。与完整侧相比,6 - 羟基多巴胺损伤未改变D1受体,增加了D2受体,降低了D3受体和多巴胺转运体。结果表明,突触后D1、D2或D3受体可介导多巴胺对丘脑底核神经元活动的影响。D4受体仅介导突触前效应。这些结果强化了这样一种观点,即丘脑底核中的多巴胺受体可能在基底神经节的生理学以及帕金森病的病理生理学中发挥重要作用。